Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Somatropin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2028 · 703 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Somatropin (ATC-Code nach WHO: H01AC01)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers. Revenue is unpredic...

Multiple suppliers can join, so no exclusive supply rights. Competition may reduce individual sales.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Supply of pharmaceutical products containing Somatropin (ATC H01AC01)
  • Non-exclusive discount agreement under §130a Abs. 8 SGB V
Afficher le résumé complet

This is a non-exclusive drug discount agreement (Rabattvereinbarung) for the active substance Somatropin (ATC H01AC01) under an Open-House model, organized by AOK PLUS for Saxony and Thuringia. The contract is open to all qualified pharmaceutical companies during the participation period. No individual negotiations, no exclusivity, no guaranteed minimum purchase quantities. The agreement ends by 31 July 2028. The procedure is not a public procurement in the traditional sense; it uses an Open-House model. The first submission deadline is 7 July 2026, with rolling deadlines thereafter. No estimated value is provided. Confidentiality and strict handling of documents are required.

Risques

No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers. Revenue is unpredic...

Multiple suppliers can join, so no exclusive supply rights. Competition may reduce individual sales.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG
  • No Russia sanctions connection per EU Regulation 833/2014

Eligibility

  • No exclusion grounds under §§123, 124 GWB

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Somatropin

Non-exclusive discount agreement for Somatropin (ATC H01AC01) via Open-House model. No exclusivity, no minimum volumes. Contract ends 31 July 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 31, 2028

Détails de la procédure

Date de publication
19 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
345458-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30